Integrating HIV and hypertension management in low-resource settings: Lessons from Malawi

English version České info

Pragna Patel and colleagues describe the implementation of a hypertension management model for HIV-infected people in Malawi.

Vyšlo v časopise: Integrating HIV and hypertension management in low-resource settings: Lessons from Malawi. PLoS Med 15(3): e32767. doi:10.1371/journal.pmed.1002523
Kategorie: Health in Action
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002523

Souhrn

Pragna Patel and colleagues describe the implementation of a hypertension management model for HIV-infected people in Malawi.

Zdroje

1. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 386 (10010):2287–2323. doi: 10.1016/S0140-6736(15)00128-2 26364544

2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study. Lancet. 2015 Jan 10;385(9963):117–71. doi: 10.1016/S0140-6736(14)61682-2 25530442

3. WHO. STEPS Country Reports 2013. Available from: http://www.who.int/chp/steps/reports/en/.

4. Lessells RJ, Mutevedzi PC, Iwuji CC, Newell ML. Reduction in early mortality on antiretroviral therapy for adults in rural South Africa since change in CD4+ cell count eligibility criteria. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):e17–24. doi: 10.1097/QAI.0b013e31829ceb14 23756374

5. Mensah GA, Roth GA, Sampson UK, Moran AE, Feigin VL, Forouzanfar MH, et al.; GBD 2013 Mortality and Causes of Death Collaborators. Mortality from cardiovascular diseases in sub-Saharan Africa, 1990–2013: a systematic analysis of data from the Global Burden of Disease Study 2013. Cardiovasc J Afr. 2015; 26(2 Suppl 1):S6–10.

6. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, et al. All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41:433–445. doi: 10.1093/ije/dyr164 22493325

7. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13: 453–468. doi: 10.1111/j.1468-1293.2012.00996.x 22413967

8. Hendriks ME, Wit FWNM, Roos MTL, Brewster LM, Akande TM, de Beer IH, et al. Hypertension in Sub-Saharan Africa: Cross-Sectional Surveys in Four Rural and Urban Communities. PLoS ONE. 2012;7(3): e32638. doi: 10.1371/journal.pone.0032638 22427857

9. Ripple Africa. General information about healthcare in Malawi. Available from: https://www.rippleafrica.org/healthcare-in-malawi-africa/healthcare-in-malawi-africa

10. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand T, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006; 368:505–10. doi: 10.1016/S0140-6736(06)69158-7 16890837

11. WHO. Everybody business: strengthening health systems to improve health outcomes: WHO’s framework for action. 2007. Available from: http://www.who.int/healthsystems/strategy/everybodys_business.pdf

12. Van Mourik MS, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010; 10:25. doi: 10.1186/1471-2261-10-25 20534118

13. Angell SY, DeCock KM, Frieden TR. A public health approach to global management of hypertension. Lancet. 2015;385:825–27. doi: 10.1016/S0140-6736(14)62256-X 25752181

14. Peyriere H, Eiden C, Macia JC, Reynes J. Antihypertensive Drugs in Patients Treated with Antiretrovirals. Ann Pharmacother. 2012;46:703–9. doi: 10.1345/aph.1Q546 22550277

15. Baker JV, Hullsiek KH, Prosser R, Duprez D, Grimm R, Tracy RP, et al. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. PLoS ONE. 2012;7(10): e46894. doi: 10.1371/journal.pone.0046894 23082133

16. Onusko E. Diagnosing secondary hypertension. Am Fam Physician. 2003; 67(1): 67–74. 12537168

17. Bickett DP. Using ACE Inhibitors appropriately. Am Fam Physician. 2002; 66(3):461–9. 12182524

18. Thompson-Paul AM, Lichtenstein KA, Armon C, Buchacz K, Debes R, Chmiel JS, et al. Cardiovascular disease risk prediction in the HIV Outpatient Study (HOPS). In: Conference on Retroviruses and Opportunistic Infections; 2015 February 23–26; Seattle, Washington (WA). Abstract number 747.

19. Suthar AB, Rutherford GW, Horvath T, Doherty MC, Negussie EK. Improving antiretroviral therpay scale-up and effectiveness through service integration and decentralization. AIDS. 2014; 28(Suppl 2):S175–S185.

20. Sharma M, Ying R, Tarr G, Barnabas R. Systematic review and meta-analysis of community and facility-based HIV testing to address linkage to care gaps in SSA. Nature. 2015; 528: S77–S85. doi: 10.1038/nature16044 26633769

21. Atun R, de Jongh T, Secci F, Ohiri, Adeyi O. A systematic review of the evidence on integration of targeted health interventions into health systems. Health Policy and Planning 2010;25:1–14. doi: 10.1093/heapol/czp053 19959485

22. WHO. Global Action Plan for The Prevention and Control of Noncommunicable diseases 2013–2020. 2013. Available from: http://www.who.int/nmh/events/ncd_action_plan/en/.